-+ 0.00%
-+ 0.00%
-+ 0.00%

Daiichi Sankyo’s Datroway wins CHMP backing for EU approval in first-line metastatic TNBC

PUBT·06/26/2026 11:01:06
Listen to the news
Daiichi Sankyo’s Datroway wins CHMP backing for EU approval in first-line metastatic TNBC
  • EMA’s CHMP recommended EU approval of Datroway for first-line metastatic triple-negative breast cancer patients not eligible for PD-1/PD-L1 inhibitors.
  • Opinion based on TROPION-Breast02 phase 3 data showing median overall survival of 23.7 months vs 18.7 months with chemotherapy.
  • European Commission to decide on the marketing authorization; Datroway is co-developed with AstraZeneca.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daiichi Sankyo Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606260700BIZWIRE_USPR_____20260625_BW475660) on June 26, 2026, and is solely responsible for the information contained therein.